Home > Healthcare > Medical Devices > Diagnostic Devices > Radiotheranostics Market

Radiotheranostics Market Size

  • Report ID: GMI8785
  • Published Date: Apr 2024
  • Report Format: PDF

Radiotheranostics Market Size

Radiotheranostics Market size was valued at around USD 2 billion in 2023 and is anticipated to register a CAGR of over 14.6% between 2024 and 2032. Radiotheranostics is a medical approach that combines the principles of radiotherapy and diagnostics utilizing radiopharmaceuticals for both therapeutic treatment and diagnostic imaging.

 

This integrated approach allows for personalized and targeted management of various diseases particularly cancer and certain other conditions. Radiotheranostics involves the use of radiopharmaceuticals labeled with radioactive isotopes emitting radiation suitable for imaging and therapy. The increasing prevalence of cancer is a significant driver for the market.
 

For instance, according to World Health Organization (WHO) in 2020, reported that cancer emerged as a prominent contributor to global mortality, claiming approximately 10 million lives globally. Thus, the demand for radiotheranostics offers a vital dual approach of precise diagnosis and targeted therapy to improved patient outcomes. Furthermore, market growth is attributed to multiple factors, including the growing use of radiotheranostics in cancer diagnostics, which estimated to reach USD 324 billion by 2032, and management and increasing trend of nuclear medicine.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global radiotheranostics industry reached USD 2 billion in 2023 and is estimated to record over USD 6.6 billion by 2032, driven by the growing use of radiotheranostics in cancer diagnostics.

The targeted therapeutics approach segment in the market a decent share in 2023 and is expected to reach USD 4 billion by 2032, driven by personalized treatments leading to more effective outcomes.

North America radiotheranostics industry accounted for USD 798.3 million in revenue in 2023 and is predicted to witness substantial growth over the analysis timeline, owing to a well-developed healthcare infrastructure.

Life Healthcare Group, Nordic Nanovector ASA, Novartis AG, Progenics Pharmaceuticals, Inc, Q BioMed Inc., QSAM Biosciences, Inc., RadioMedix, Radiopharm Theranostics Limited among others

Radiotheranostics Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 10
  • Tables & Figures: 233
  • Countries covered: 22
  • Pages: 190
 Download Free Sample